Hinge Health Inc. (NYSE:HNGE) Stock Has Average Price Target of $105.33 According to Brokerages - MarketBeat
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nineteen research firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $105.33. 3 Healthcare Stocks Showing Why the Sector Still Has MomentumSeveral equities analysts recently issued reports on HNGE shares. Truist Financial lifted their price target on shares of Hinge Health from $85.00 to $112.00 and gave the company a "buy" rating in a report on Monday, August 10th. Robert W. Baird upped their price objective on shares of Hinge Health from $85.00 to $90.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 22nd. Bank of America began coverage on shares of Hinge Health in a report on Tuesday, September 29th. They set a "buy" rating and a $110.00 price objective for the company.
This article is an excerpt. To read the full content, visit the original source. MarketBeat
Related articles
Live Nation Entertainment, Inc. (NYSE:LYV) Stock Has Consensus Target Price of $197.19 According to Brokerages - MarketBeat
Shares of Live Nation Entertainment, Inc. (NYSE:LYV - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-four analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $197.19. 3 Big Earnings Misses: Is It Time to Buy the Dip? A number of equities analysts have recently weighed in on LYV shares. Zacks Research raised shares of Live Nation Entertainment from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. The Goldman Sachs Group lifted their price objective on Live Nation Entertainment from $192.00 to $202.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their price objective on Live Nation Entertainment from $180.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, July 21st.
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!